Ready to get your patient started on therapy?

Once you have identified an appropriate patient for a multiple myeloma bispecific therapy, these actions may help prepare your patients and care partners for the treatment journey. 

To foster an efficient and seamless treatment experience for your patient and to help mitigate potential treatment issues, determine your patient’s care plan, including dosing schedules, site(s) of administration, and prophylaxis procedures.

Topics may include:

  • Therapy, including how the bispecific therapy for multiple myeloma works, clinical trial results, step-up and treatment dosing, potential side effects and complications, dosing schedule, and care plan
  • Care partner training, including monitoring for signs and symptoms of potential side effects and what to do in case of an emergency
  • Logistical support, such as transportation, lodging, and meals
  • Financial considerations, including estimated cost of therapy (accounting for insurance coverage), care partner support, visiting nurse services, and loss of work

Consider developing an informational packet for patients and care partners that includes the names of relevant team members, their roles and responsibilities, important phone numbers, who to contact at different times of the day, when to reach out to report symptoms, and when/where to go if they require hospitalization.

These programs can support your patient through their treatment journey by offering access assistance, affordability resources, and more. While each program varies, patients may receive customized support throughout their unique treatment journey. Additional details regarding patient support programs can be found in the J&J Resource Library.

Explore Resources

Need more?

Access the multiple myeloma bispecifics Resource Library from Johnson & Johnson for tools to support your operational readiness.

Access the multiple mye...

Researcher Image: A researcher using advanced technology in a lab to develop innovative treatments for multiple myeloma patients.

Learn more about the bispecific antibody therapies for multiple myeloma from Johnson & Johnson.

Learn more

Have additional questions about the operational process of treating multiple myeloma with bispecifics?

Learn more